Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy

In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors

(2013) Mahiuddin Ahmed et al.   PLoS One

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

(2012) M. Klinger et al.   BLOOD

Phase II trial of hu14.18-IL2 for patients with metastatic melanoma

(2012) Mark R. Albertini et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Trifunctional Bispecific Antibodies Induce Tumor-Specific T Cells and Elicit a Vaccination Effect

(2012) Nina Eissler et al.   CANCER RESEARCH

Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission

(2012) Nai-Kong V. Cheung et al.   JOURNAL OF CLINICAL ONCOLOGY

Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model

(2012) Peter Ruf et al.   Journal of Translational Medicine

Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma

(2012) B. D. Choi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Towards a universal disulphide stabilised single chain Fv format: importance of interchain disulphide bond location and vL-vH orientation

(2012) E. E. Weatherill et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo

(2012) Nai-Kong V. Cheung et al.   OncoImmunology

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells

(2011) Jerome Thiery et al.   NATURE IMMUNOLOGY

Genotypes of NK Cell KIR Receptors, Their Ligands, and Fc  Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy

(2010) D. C. Delgado et al.   CANCER RESEARCH

Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR

(2010) Jennifer S. Michaelson et al.   mAbs

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells

(2010) Ralf Lutterbuese et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reducing Epitope Spread during Affinity Maturation of an Anti-Ganglioside GD2 Antibody

(2009) J. Hu et al.   JOURNAL OF IMMUNOLOGY

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE